Indian companies are racing to launch protein-rich foods, collagen supplements and face fillers to capitalise on side effects from the growing use of GLP-1 weight-loss drugs such as Ozempic and Mounjaro.
Starbucks will stop covering GLP-1 weight-loss drugs under its employee health plans from October, the coffee chain has confirmed to Business Insider. The medicines will still be available for diabetes and other…
Bank of America plans to spend $250 million a year on GLP-1 medicines, NDTV Profit reports. The drugs include Ozempic and Wegovy, which have seen rising demand. Each patient’s treatment can cost…
